相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments
Christian Dide-Agossou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Chapter 3: Diagnosis of tuberculosis disease and drug-resistant tuberculosis
Marcel A. Behr et al.
CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE (2022)
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity
Solomon P. le Roux et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis Results from a Randomized Clinical Trial
Kamunkhwala Gausi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
An overview of new antitubercular drugs, drug candidates, and their targets
Aparna Bahuguna et al.
MEDICINAL RESEARCH REVIEWS (2020)
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
Alan Faraj et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development
Budi O. Susanto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis
Oskar Clewe et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2020)
Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
Alan Faraj et al.
SCIENTIFIC REPORTS (2020)
Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients
Michael A. Lyons
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations
Chunli Chen et al.
AAPS JOURNAL (2018)
Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
Sebastian G. Wicha et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations
Robin J. Svensson et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
Robin J. Svensson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods
Robin J. Svensson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB
Elin M. Svensson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
Chunli Chen et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
Oskar Clewe et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling
Anne-Gaelle Dosne et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis
R. J. Svensson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin J. Boeree et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations
Ruth Bowness et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
The early bactericidal activity of antituberculosis drugs
Andreas H. Diacon et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media
Jasvir Dhillon et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture
Emmanuel Chigutsa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
R. J. Keizer et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents
A. H. Diacon et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Resuscitation-promoting Factors Reveal an Occult Population of Tubercle Bacilli in Sputum
Galina V. Mukamolova et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Letting Sleeping dos Lie: Does Dormancy Play a Role in Tuberculosis?
Michael C. Chao et al.
ANNUAL REVIEW OF MICROBIOLOGY, VOL 64, 2010 (2010)
Targeting non-multiplying organisms as a way to develop novel antimicrobials
Anthony R. M. Coates et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
分享论文
